Please login to the form below

Not currently logged in
Email:
Password:

Former Glaxo CEO Ernest Mario to chair Chimerix

Pharma veteran has previously also served as CEO of Alza and Reliant

Chimerix Ernest MarioChimerix has appointed pharma veteran and former CEO of Glaxo Holdings Dr Ernest Mario as the company's new chairman.

Mario (pictured right) was CEO of Glaxo from 1989 to 1993, ahead of its subsequent merger with Wellcome in 1995 and then SmithKline Beecham in 2000 to eventually form GlaxoSmithKline (GSK).

Following his departure from Glaxo, Dr Mario served as chairman and CEO of Alza from 1993 until its acquisition by Johnson & Johnson (J&J) in 2011.

He then held the role of chairman and CEO of Reliant Pharmaceutical from 2003 until its acquisition by GSK in 2007.

Dr Mario currently serves as chairman and CEO of US-based biopharma Capnia.

"Ernie brings to Chimerix a unique breadth and depth of experiences across large and early stage pharmaceutical firms,” said Kenneth Moch, president and CEO of Chimerix.

“His knowledge will be invaluable as we seek to progress our lead compound, CMX001, through phase III clinical development and commercial launch."

Dr Mario replaces Dr James Niedel, who will remain as a member of the board at Chimerix.

26th February 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...

Infographics